A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease. - Nathan PJ; Millais SB; Godwood A; Dewit O; Cross DM; Liptrot J; Ruparelia B; Jones SP; Bakker G; Maruff PT; Light GA; Brown AJH; et al. (Alzheimer's & dementia (New York, N. Y.), 2022)